BryanLGH Heart Institute Participating in Investigational Study Evaluating Use Of Implantable Pulse Generator
Posted on: Thursday, 4 August 2005, 09:01 CDT
LINCOLN, Neb., Aug. 4 /PRNewswire/ -- BryanLGH Heart Institute today announced it is participating in a clinical study and has performed its first successful implant to investigate the safety and effectiveness of a new implantable pulse generator called the Optimizer(TM). The Optimizer(TM) System is designed to deliver electrical impulses to the heart for treatment of moderate to severe heart failure. This study of the Optimizer System is sponsored by Impulse Dynamics (USA) Inc., a specialty medical device company located in New York and a wholly-owned subsidiary of Impulse Dynamics N.V.
Heart failure is a disease that afflicts over 5 million Americans and an estimated 15 million patients worldwide. It is one of the most common causes of hospitalization and a growing and costly burden to the healthcare system. It is estimated that the U.S. healthcare system will spend a projected $28.8 billion on caring for heart failure patients in 2005.
Heart failure is a disease caused by a weak or damaged heart muscle that is unable to pump enough blood throughout the body. If proven safe and effective, the Optimizer System has the potential to help treat heart failure in a large number of patients.
"The Optimizer System is an exciting technology with the potential to treat patients with Class III or Class IV heart failure," said Dr. Andrew Merliss, Principle Investigator. "We have already begun enrolling patients in the FIX-HF-5 Study to evaluate the safety and effectiveness of the Optimizer System. We look forward to completing new patient enrollment in order to fully assess the potential of this device to meet the needs of moderate to severe heart failure patients."
The investigational study, called FIX-HF-5 (Fix Heart Failure 5), is designed to investigate the effects of the Optimizer System in approximately 400 New York Heart Association (NYHA) Class III or Class IV heart failure patients at up to 50 U.S. sites.
About Heart Failure
Symptoms of heart failure result when the heart is unable to pump enough blood to meet the energy needs of the body. A failing heart most often results from damage to the heart muscle due to injuries such as heart attack, untreated coronary artery disease or persistent high blood pressure. It can also occur as a result of genetic and/or molecular abnormalities or infections. The most common forms of heart failure are treated with drugs and electrical devices such as pacemakers and implanted defibrillators, but if symptoms continue to worsen, other therapies are needed.
About BryanLGH Heart Institute
The BryanLGH Heart Institute (BHI) is a cardiovascular medical group specializing in cardiology and cardiovascular and thoracic surgery. BHI is dedicated to the most advanced diagnosis and treatment of heart disease while remaining patient focused. We focus on personal relationships with patients and communities while providing the most effective cardiovascular care available.
BHI is currently staffed with eleven physicians serving a four-state region, based in Lincoln, Nebraska. Services are routinely performed in more than 30 communities.
BryanLGH Heart Institute
CONTACT: Dr. Andrew Merliss, Principle Investigator, +1-402-483-3333, orJill Domsch, Public Relations, +1-402-483-3333, jill@bhi-1.com; both forBryanLGH Heart Institute
Source: PRNewswire
Related Articles
- American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure Patients
- Heart Failure In Patients With Quivering Heart
- Biogen Idec Initiates Phase III Clinical Trial for ADENTRI(R) in Acute Decompensated Heart Failure Patients With Renal Insufficiency
- Study Data Shows Gaps and Variation in the Use of Evidence-Based Treatments and Guidelines for Chronic Heart Failure
- New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients With Coronary Heart Disease
- MultiVu Video Feed: Intensive Lipitor Therapy Cuts The Risk of Hospitalizations Due to Heart Failure in Patients With Coronary Heart Disease, New Analysis Shows
- Statin Use Associated With Lower Risks of Death and Hospitalization for Heart Failure Patients
- Pioglitazone Did Not Reduce a Composite Endpoint of Macrovascular Complications and Increased Risk for Heart Failure in Type 2 Diabetes With Macrovascular Disease/COMMENTARY
- Marker for Heart Failure Works in Kidney Patients
- Soarian Disease Management Helps Improve Care of Congestive Heart Failure Patients; Siemens Announces General Availability of Latest Healthcare IT Innovation
User Comments (1)
| 1. |
Posted by Tonya Aultman on 01/01/2007, 11:40 Have there been any studies on children with congenital heart disease with this device? I am very interested in this study, if possible, can I please get a reply on my email at mkdaisy73@yahoo.com ? Thank you. |

RSS Feeds